As shown in figure 1E, no significant difference in the secretion of IFN-γ was observed after co-culturing individual peptide-pulsed HER2-DC1 with tumor draining lymph nodes (TDLNs) and non-draining lymph nodes (NDLNs) from the HER2-DC1 s.c., anti-HER2 antibodies or HER2-DC1 s.c. in combination with anti-HER2 antibodies treatment groups. This evidence concerns the gene ERBB2 and neoplasm.